ADARx Pharmaceuticals, Inc.

NASDAQ:ADRX

Biotechnology

Healthcare
$12.82 +0.73%

+$0.13 today

Market cap
$1.42B
Beta
0.00
52W Low $16.64High $23.21

Volume 0.65M

Average 1.06M

ADRX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

No reported EBITDA figures are available to summarize.

EBITDA history

Currency unavailable · from the income statement

No EBITDA data reported for this period type.

EBITDA vs competitors

How ADRX compares with its peers on the latest reported figures

ADRX Competitors
EBITDA for ADRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$53.46M USD-44.4%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$67.53M USD-3.7%—148.9%
RNAAtrium Therapeutics, Inc.FY2025-$76.5M USD——410.9%
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
MGTXMeiraGTx Holdings plcLTM Mar 2026-$95.72M USD+32.5%—120.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026-$164.11M USD-405.9%—511.5%
WVEWave Life Sciences Ltd.LTM Mar 2026-$174.59M USD-68.4%—243.2%
PRMEPrime Medicine, Inc.LTM Mar 2026-$190.9M USD+2.4%—4732.2%
ADRXADARx Pharmaceuticals, Inc.—— ———
Peer median (excluding ADRX) —-44.4%—365.0%

Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

ADARx Pharmaceuticals, Inc.

NASDAQ:ADRX

Intrinsic Alpha fair value

Locked

Current Price

$12.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.